Erratum: Therapeutic targeting of ATP7B in ovarian carcinoma (Clinical Cancer Research (2009) 15 (3770-3780) DOI: 10.1158/1078-0432.CCR-08-2306);Therapeutic targeting of ATP7B in ovarian carcinoma

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3770-3780

  Mangala, Lingegowda S ^a   Zuzel, Vesna ^e   Schmandt, Rosemarie ^a   Leshane, Erik S ^e   Halder, Jyotsna B ^a   Armaiz Pena, Guillermo N ^a,b   Spannuth, Whitney A ^a   Tanaka, Takemi ^d   Shahzad, Mian M K ^a,c   Lin, Yvonne G ^a   Nick, Alpa M ^a   Danes, Christopher G ^a   Lee, Jeong Won ^a,f   Jennings, Nicholas B ^a   Vivas Mejia, Pablo E ^a   Wolf, Judith K ^a   Coleman, Robert L ^a   Siddik, Zahid H ^a   Lopez Berestein, Gabriel ^a   Lutsenko, Svetlana ^e   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DIOLEOYLPHOSPHATIDYLCHOLINE; MENKES PROTEIN; SMALL INTERFERING RNA; WILSON DISEASE PROTEIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATP7A GENE; ATP7B GENE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA ADDUCT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 66649118310     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-21-2120     Document Type: Erratum

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
3. Sood AK, Buller RE. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol 1998;92:312-319 (Pubitemid 28350871)
4. Leyland-Jones B, Kelland LR, Harrap KR, Hiorns LR. Genomic imbalances associated with acquired resistance to platinum analogues. Am J Pathol 1999;155:77-84. (Pubitemid 29318706)
5. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000;59 Suppl 4:1-8, discussion 37-38 (Pubitemid 30344986)
6. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998;34:1535-1542 (Pubitemid 28446333)
7. Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res 2003;9:5807-5809 (Pubitemid 38018060)
8. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990;21:34-48. (Pubitemid 20042403)
9. Douple EB. cis-Diamminedichloroplatinum(II): effects of a representative metal coordination complex on mammalian cells. Pharmacol Ther 1984;25:297-326. (Pubitemid 15206079)
10. Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999;125:156-165 (Pubitemid 29172506)
11. Samimi G, Fink D, Varki NM, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000;6:1415-1421 (Pubitemid 30226229)
12. Ooi CE, Rabinovich E, Dancis A, Bonifacino JS, Klausner RD. Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO J 1996;15:3515-3523 (Pubitemid 26239763)
13. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 2003;64:466-473 (Pubitemid 36910011)
14. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559-6565 (Pubitemid 35364122)
15. Qian Y, Tiffany-Castiglioni E, Harris ED. Copper transport and kinetics in cultured C6 rat glioma cells. Am J Physiol 1995;269:C892-8.
16. Katano K, Safaei R, Samimi G, et al. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 2004;10:4578-4588 (Pubitemid 38878902)
17. Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004;10:4661-4669 (Pubitemid 38955516)
18. Ohbu M, Ogawa K, Konno S, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. Cancer Lett 2003;189:33-38 (Pubitemid 35351517)
19. Kanzaki A, Toi M, Neamati N, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn J Cancer Res 2002;93:70-77 (Pubitemid 34144714)
20. Higashimoto M, Kanzaki A, Shimakawa T, et al. Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma. Int J Mol Med 2003;11:337-341
21. Nakayama K, Kanzaki A, Terada K, et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 2004;10:2804-2811 (Pubitemid 38509159)
22. Sugeno H, Takebayashi Y, Higashimoto M, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma. Anticancer Res 2004;24:1045-1048 (Pubitemid 38624935)
23. Miyashita H, Uchida T, Mori S, Echigo S, Motegi K. Expression status of Pin1 and cyclins in oral squamous cell carcinoma: Pin1 correlates with cyclin D1 mRNA expression and clinical significance of cyclins. Oncol Rep 2003;10:1045-1048
24. Aida T, Takebayashi Y, Shimizu T, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol 2005;97:41-45 (Pubitemid 40403672)
25. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993;3:7-13. (Pubitemid 23063281)
26. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327-337 (Pubitemid 23351302)
27. Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. Physiol Rev 2007;87:1011-1046 (Pubitemid 47084675)
28. Landen CN, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-6918 (Pubitemid 41060730)
29. Halder J, Kamat AA, Landen CN, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-4924 (Pubitemid 44338579)
30. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-1288 (Pubitemid 32281292)
31. Halder J, Landen CN, Lutgendorf SK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005;11:8829-8836 (Pubitemid 43005935)
32. Lutsenko S, Petrukhin K, Cooper MJ, Gilliam CT, Kaplan JH. N-terminal domains of human copper-transporting adenosine triphosphatases (the Wilson's and Menkes disease proteins) bind copper selectively in vivo and in vitro with stoichiometry of one copper per metal-binding repeat. J Biol Chem 1997;272:18939-18944 (Pubitemid 27318247)
33. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-284 (Pubitemid 29210167)
34. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239 (Pubitemid 37204044)
35. Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007;67:9337-9345 (Pubitemid 47535923)
36. Bartee MY, Lutsenko S. Hepatic copper-transporting ATPase ATP7B: function and inactivation at the molecular and cellular level. Biometals 2007;20:627-637 (Pubitemid 46778684)
37. Lutsenko S, LeShane ES, Shinde U. Biochemical basis of regulation of human copper-transporting ATPases. Archiv Biochem Biophys 2007;463:134-148 (Pubitemid 47030341)
38. DiDonato M, Narindrasorasak S, Forbes JR, Cox DW, Sarkar B. Expression, purification, and metal binding properties of the N-terminal domain from the Wilson disease putative copper-transporting ATPase (ATP7B). J Biol Chem 1997;272:33279-33282 (Pubitemid 28023676)
39. Walker JM, Huster D, Ralle M, Morgan CT, Blackburn NJ, Lutsenko S. The N-terminal metal- binding site 2 of the Wilson's disease protein plays a key role in the transfer of copper from Atox1. J Biol Chem 2004;279:15376-15384 (Pubitemid 38618936)
40. Li S-D, Chen Y-C, Hackett MJ, Huang L. Tumor- targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2007;161:163-169.
41. Lowndes SA, Harris AL. The role of copper in tumour angiogenesis. J Mamm Gland Biol Neoplasia 2005;10:299-310. (Pubitemid 44256410)
42. Goodman VL, Brewer GJ, Merajver SD. Control of copper status for cancer therapy. Curr Cancer Drug Targets 2005;5:543-549 (Pubitemid 41502565)
43. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43. (Pubitemid 20218552)
44. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279 (Pubitemid 37487159)
45. Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 2002;101:488-495
46. Leonhardt K, Gebhardt R, Mossner J, Lutsenko S, Huster D. Functional interactions of CU-ATPase ATP7B with cisplatin and the role of ATP7B in cells resistance to the drug. J Biol Chem 2009;284:7793-7802
47. Komatsu M, Sumizawa T, Mutoh M, et al. Copper- transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000;60:1312-1316 (Pubitemid 30152000)
48. Huster D, Purnat TD, Burkhead JL, et al. High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem 2007;282:8343-8355 (Pubitemid 47093558)